Fig. 1.

The SRC-3 activator MCB-613 attenuates loss of cardiac function post-MI. (A) Ejection fraction was measured by echocardiography at the indicated times. Values shown are mean ± SEM; two-way ANOVA with repeated measures. n = 10 control and n = 11 MCB-613. Day 14 **P 0.0078. Day 80 **P = 0.008. (B) Control-treated hearts (n = 3) and MCB-613-treated hearts (n = 3) stained with picrosirius red. Quantification of percent fibrosis. Student’s t test for fibrosis (*P = 0.03). (C) Values shown are mean ± SEM; Student’s t test for HW/TL (n = 6); (*P = 0.03).